Novartis ties a new round of biosimilar development programs to a partnership deal with India's Biocon
Just a few weeks after Biocon and their partners at Mylan worked out an FDA approval for the first Herceptin biosimilar, the Indian company has struck a wide ranging development deal with Novartis’ generics arm.
Biocon and Sandoz — which has already developed a slate of 5 biologic knockoffs — will go to work on immunology and oncology programs together. They plan to share development, manufacturing and regulatory costs while splitting the profits on “a number” of new therapies.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.